Pilot results from #IP2ATLANTA on novel cytoreductive treatments to the prostate & mets in de novo mHSPC presented by @londonprostate1.bsky.social #AUA25 🇺🇸

Take home - these treatments are safe and justified

Recruitment for the main trial has completed - PFS endpoint to be reported 2027

#IP2ATLANTA RCT pilot result #EAU25 🇪🇸

🔬 9 in 10 patients have a viable prostate tumour despite ADT+ARTA/Doce

🚦Early signal in prostate cancer mortality for cytoreductive arms

📈 Surgery, radiotherapy or ablation + SABR safe - Recruited (n=433) PFS exp.2027!

@connorurol.bsky.social

It’s a big last day at #EAU25 for our team! 🇪🇸

@connorurol.bsky.social - 2x #IP2ATLANTA pilot study results (12:00)

Mr Chase Ng - #RAPID 5-yr follow-up for negative biopsy patients (12:05)

Mr Nikhil Mayor - #IP8FLUORESCE late breaking results (12:15)

📣 Join Clinical Lecturer Mr Martin Connor as he presents the first Imperial Prostate randomised controlled trial - #IP2ATLANTA internal pilot results are out!

Live on Monday 12:00 ⏱️ #EAU25 🇪🇸

#CytoreductiveSurgery #SABR #Ablation @connorurol.bsky.social @londonprostate1.bsky.social